{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:33:41Z","timestamp":1790876021565,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.mayocp.2018.03.025","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T11:15:26Z","timestamp":1527851726000},"page":"794-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Updates in the Evaluation and Management of Breast Cancer"],"prefix":"10.1016","volume":"93","author":[{"given":"Ciara C.","family":"O'Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tufia C.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1055-9965.EPI-16-0858","article-title":"Global cancer in women: burden and trends","volume":"26","author":"Torre","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.mayocp.2018.03.025_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/GCO.0000000000000343","article-title":"Breast cancer: updates and advances in 2016","volume":"29","author":"Giordano","year":"2017","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10549-017-4408-0","article-title":"Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants","volume":"166","author":"Lukong","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.mayocp.2018.03.025_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/cncr.20978","article-title":"Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?","volume":"103","author":"Fregene","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1634\/theoncologist.2016-0430","article-title":"Systemic treatment strategies for patients with hereditary breast cancer syndromes","volume":"22","author":"Parkes","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3322\/caac.21225","article-title":"Priorities for the primary prevention of breast cancer","volume":"64","author":"Colditz","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.mcna.2017.03.005","article-title":"Risk-based breast cancer screening: implications of breast density","volume":"101","author":"Lee","year":"2017","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/2053369117715370","article-title":"Hormonal contraception and breast cancer, what more do we need to know?","volume":"23","author":"Marsden","year":"2017","journal-title":"Post Reprod Health"},{"issue":"12","key":"10.1016\/j.mayocp.2018.03.025_bib9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/aje\/kwx206","article-title":"Epidemiologic risk factors for in situ and invasive breast cancers among postmenopausal women in the National Institutes of Health\u2013AARP Diet and Health Study","volume":"186","author":"Mullooly","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"9328","key":"10.1016\/j.mayocp.2018.03.025_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(02)09454-0","article-title":"Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mayocp.2018.03.025_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/0284186X.2014.998275","article-title":"Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies","volume":"54","author":"Lahart","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.mayocp.2018.03.025_bib12","series-title":"Diseases of the Breast","article-title":"Pathology of invasive breast cancer","author":"Dillon","year":"2014"},{"issue":"31","key":"10.1016\/j.mayocp.2018.03.025_bib13","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2018.03.025_bib14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2018.03.025_bib15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2018.03.025_bib16","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.mayocp.2018.03.025_bib17","author":"American Joint Committee on Cancer (AJCC)"},{"issue":"6797","key":"10.1016\/j.mayocp.2018.03.025_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.mayocp.2018.03.025_bib19","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.mayocp.2018.03.025_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5858\/arpa.2016-0288-SA","article-title":"New developments in breast cancer and their impact on daily practice in pathology","volume":"141","author":"Li","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"24","key":"10.1016\/j.mayocp.2018.03.025_bib22","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-10-1533","article-title":"Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study","volume":"16","author":"O'Brien","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.mayocp.2018.03.025_bib23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.mayocp.2018.03.025_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jnci\/50.5.1111","article-title":"On the origin and progression of ductal carcinoma in the human breast","volume":"50","author":"Wellings","year":"1973","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.mayocp.2018.03.025_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ctrv.2017.03.009","article-title":"Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast","volume":"55","author":"Mart\u00ednez-P\u00e9rez","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2018.03.025_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10549-010-1198-z","article-title":"Ductal carcinoma in situ: trends in treatment over time in the US","volume":"127","author":"Zujewski","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2018.03.025_bib27","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.breast.2007.07.015","article-title":"The dilemma of DCIS","volume":"16","author":"Morrow","year":"2007","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.mayocp.2018.03.025_bib28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjsurg.2013.07.001","article-title":"Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast","volume":"206","author":"Sue","year":"2013","journal-title":"Am J Surg"},{"issue":"33","key":"10.1016\/j.mayocp.2018.03.025_bib29","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2016.68.3573","article-title":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ","volume":"34","author":"Morrow","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0093-7754(01)90133-2","article-title":"Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience","volume":"28","author":"Fisher","year":"2001","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2018.03.025_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2018.03.025_bib32","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO.2006.06.1366","volume":"24","author":"Bijker","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9378","key":"10.1016\/j.mayocp.2018.03.025_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0140-6736(03)13859-7","article-title":"Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial","volume":"362","author":"Houghton","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mayocp.2018.03.025_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/02841860600681569","article-title":"SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening","volume":"45","author":"Emdin","year":"2006","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.03.025_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2018.03.025_bib36","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10021","key":"10.1016\/j.mayocp.2018.03.025_bib37","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"},{"issue":"10021","key":"10.1016\/j.mayocp.2018.03.025_bib38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","article-title":"Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Ganz","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2018.03.025_bib40","author":"National Comprehensive Cancer Network"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/annonc\/mdi063","article-title":"Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications","volume":"16","author":"Puglisi","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.adro.2016.09.002","article-title":"Oncoplastic breast surgery in the setting of breast-conserving therapy: a systematic review","volume":"1","author":"Yoon","year":"2016","journal-title":"Adv Radiat Oncol"},{"issue":"10074","key":"10.1016\/j.mayocp.2018.03.025_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2018.03.025_bib44","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.2014.10707","article-title":"Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011","volume":"312","author":"Kurian","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2018.03.025_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJMsb1202521","article-title":"Surgical margins in lumpectomy for breast cancer\u2013bigger is not better","volume":"367","author":"Morrow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2018.03.025_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1245\/s10434-016-5756-4","article-title":"Intraoperative margin management in breast-conserving surgery: a systematic review of the literature","volume":"25","author":"Gray","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"3 suppl","key":"10.1016\/j.mayocp.2018.03.025_bib47","doi-asserted-by":"crossref","first-page":"208S","DOI":"10.1245\/ASO.2004.11.909","article-title":"NSABP-32: phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial","volume":"11","author":"Krag","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients","volume":"250","author":"Hunt","year":"2009","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.mayocp.2018.03.025_bib50","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/WHE.14.85","article-title":"Factors to consider in breast reconstruction","volume":"11","author":"Nahabedian","year":"2015","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.mayocp.2018.03.025_bib52","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.mayocp.2018.03.025_bib53","series-title":"ESTRO Congress Report","first-page":"6","article-title":"Lymph node radiotherapy improves survival in breast cancer: 10 year results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922\/10925","author":"Poortmans","year":"2014"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.soc.2017.01.013","article-title":"Updates in the treatment of breast cancer with radiotherapy","volume":"26","author":"Castaneda","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","article-title":"Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial","volume":"16","author":"Kunkler","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ijrobp.2017.02.094","article-title":"The use of hormone therapy alone versus hormone therapy and radiation therapy for breast cancer in elderly women: a population-based study","volume":"98","author":"Nichol","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9938","key":"10.1016\/j.mayocp.2018.03.025_bib58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000292644","article-title":"The changing role of pathology in breast cancer diagnosis and treatment","volume":"78","author":"Leong","year":"2011","journal-title":"Pathobiology"},{"issue":"10","key":"10.1016\/j.mayocp.2018.03.025_bib60","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Harris","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2018.03.025_bib61","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1200\/JCO.2017.74.0472","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update","volume":"35","author":"Krop","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2018.03.025_bib62","first-page":"1387","article-title":"A\u00a021-gene expression assay in breast cancer","volume":"374","author":"Sparano","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2018.03.025_bib63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.mayocp.2018.03.025_bib64","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"Denduluri","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.mayocp.2018.03.025_bib65","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2018.03.025_bib66","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.mayocp.2018.03.025_bib67","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.mayocp.2018.03.025_bib68","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.2016.71.4147","article-title":"Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 (NRG Oncology)","volume":"35","author":"Blum","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"9869","key":"10.1016\/j.mayocp.2018.03.025_bib69","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.mayocp.2018.03.025_bib71","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A\u00a0comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Th\u00fcrlimann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib72","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1053\/j.seminoncol.2006.08.018","article-title":"Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy","volume":"33","author":"Wheler","year":"2006","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10552-017-0888-9","article-title":"Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer","volume":"28","author":"Kwan","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"9324","key":"10.1016\/j.mayocp.2018.03.025_bib74","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib75","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.mayocp.2018.03.025_bib76","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2015.60.8620","article-title":"Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors \u22642 cm: a meta-analysis of the randomized trastuzumab trials","volume":"33","author":"O'Sullivan","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2018.03.025_bib77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer","volume":"2","author":"Dang","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib78","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"10075","key":"10.1016\/j.mayocp.2018.03.025_bib79","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2018.03.025_bib80","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Eiermann W, Robert NJ, et\u00a0al, on behalf of the BCIRG-006 Investigators. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC\u2192T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC\u2192TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Paper presented at: San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. Abstract S5-04.","DOI":"10.1158\/1538-7445.SABCS15-S5-04"},{"issue":"31","key":"10.1016\/j.mayocp.2018.03.025_bib81","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib82","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2018.03.025_bib83","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and\/or Trastuzumab Treatment Optimization trial","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.mayocp.2018.03.025_bib84","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2018.03.025_bib85","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib86","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.03.025_bib87","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"issue":"10001","key":"10.1016\/j.mayocp.2018.03.025_bib88","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"9992","key":"10.1016\/j.mayocp.2018.03.025_bib89","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2018.03.025_bib90","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.breast.2016.10.021","article-title":"Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis","volume":"31","author":"Bonotto","year":"2017","journal-title":"Breast"},{"issue":"20","key":"10.1016\/j.mayocp.2018.03.025_bib91","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2018.03.025_bib92","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10063","key":"10.1016\/j.mayocp.2018.03.025_bib93","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib94","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2018.03.025_bib95","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib96","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/annonc\/mdu015","article-title":"Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial","volume":"25","author":"Bines","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib97","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00000421-199206000-00010","article-title":"Fluoxymesterone as third line endocrine therapy for advanced breast cancer: a phase II trial of the Piedmont Oncology Association","volume":"15","author":"Schifeling","year":"1992","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib98","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10147-015-0793-8","article-title":"Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer","volume":"20","author":"Iwase","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib99","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/mpo.2950180412","article-title":"Diethylstilbestrol revisited in advanced breast cancer management","volume":"18","author":"Boyer","year":"1990","journal-title":"Med Pediatr Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2018.03.025_bib100","first-page":"1199","article-title":"Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial","volume":"70","author":"Gockerman","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"10.1016\/j.mayocp.2018.03.025_bib101","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12609-014-0155-y","article-title":"Therapeutic considerations in treating HER2-positive metastatic breast cancer","volume":"6","author":"O'Sullivan","year":"2014","journal-title":"Curr Breast Cancer Rep"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib102","first-page":"148","article-title":"Management of metastatic HER2-positive breast cancer: where are we and where do we go from here?","volume":"30","author":"Santa-Maria","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"12","key":"10.1016\/j.mayocp.2018.03.025_bib103","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26\/breast international group 03-05 study","volume":"27","author":"von Minckwitz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.mayocp.2018.03.025_bib104","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.mayocp.2018.03.025_bib105","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2018.03.025_bib106","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib107","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.mayocp.2018.03.025_bib108","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10087","key":"10.1016\/j.mayocp.2018.03.025_bib109","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mayocp.2018.03.025_bib110","first-page":"572","article-title":"Updates on the management of breast cancer brain metastases","volume":"28","author":"Lim","year":"2014","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib111","first-page":"130","article-title":"New therapeutic strategies for triple-negative breast cancer","volume":"31","author":"Sz\u00e9kely","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.mayocp.2018.03.025_bib112","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2016.06.004","article-title":"Do platinum salts fit all triple negative breast cancers?","volume":"48","author":"Gerratana","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.mayocp.2018.03.025_bib113","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2018.03.025_bib114","article-title":"Breast cancer: exploring the facts and holistic needs during and beyond treatment","volume":"5","author":"Ng","year":"2017","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.mayocp.2018.03.025_bib115","first-page":"79","article-title":"Benefits of multidisciplinary teamwork in the management of breast cancer","volume":"5","author":"Taylor","year":"2013","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"4","key":"10.1016\/j.mayocp.2018.03.025_bib116","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12609-016-0229-0","article-title":"Management of potential long-term toxicities in breast cancer patients","volume":"8","author":"O'Sullivan","year":"2016","journal-title":"Curr Breast Cancer Rep"},{"issue":"11","key":"10.1016\/j.mayocp.2018.03.025_bib117","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/pon.4281","article-title":"The psychosocial experiences of women with breast cancer across the lifespan: a systematic review","volume":"26","author":"Campbell-Enns","year":"2017","journal-title":"Psychooncology"},{"key":"10.1016\/j.mayocp.2018.03.025_bib118","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.breast.2016.04.004","article-title":"Evolving psychosocial, emotional, functional, and support needs of women with advanced breast cancer: results from the Count Us, Know Us, Join Us and Here & Now surveys","volume":"28","author":"Cardoso","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.mayocp.2018.03.025_bib119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.breast.2016.10.022","article-title":"Is it time to address survivorship in advanced breast cancer? A review article","volume":"31","author":"Di Lascio","year":"2017","journal-title":"Breast"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618302350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618302350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T22:19:04Z","timestamp":1661379544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619618302350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":117,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0025619618302350"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.03.025","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in the Evaluation and Management of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}